Acorda Therapeutics Inc. (ACOR) announced Monday morning that data from a Phase 2 study of AMPYRA Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.
Acorda Therapeutics gapped up and rose sharply during the first 45 minutes of trade Monday, before settling into a range. The stock closed up by 3.98 at $35.50 on strong volume and broke out to a new high for the year.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.